MD Anderson and Summit Medical Group launch partnership in New Jersey

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

MD ANDERSON CANCER CENTER and Summit Medical Group in New Jersey announced the launch of their partnership to create the Summit Medical Group MD Anderson Cancer Center.

An extension of MD Anderson Cancer Center at Cooper in Camden, N.J., Summit Medical Group will now be clinically and operationally integrated with MD Anderson Cancer Center in Houston.

MD Anderson Cancer Center at Cooper joined MD Anderson Cancer Network, a program of MD Anderson Cancer Center, in 2013.

With a special emphasis on continuity of care, the new center will provide integrated, multidisciplinary cancer care for patients in northern New Jersey. The program, which provides medical oncology, infusion and diagnostic imaging, is already in place at Summit Medical Group’s campus in Berkeley Heights.

Plans are underway to build a state-of-the-art, 130,000-square-foot building adjacent to Summit Medical Group’s new facility in Florham Park, with future services to include radiation oncology. Groundbreaking is expected at the new site this summer.

Table of Contents

YOU MAY BE INTERESTED IN

At the Sept. 4 meeting of the National Cancer Advisory Board, NCI Principal Deputy Director Douglas R. Lowy provided an overview of how NCI is weathering the maelstrom of executive orders, policy changes, and funding uncertainties that has come down on federal agencies and research institutes since Donald Trump’s inauguration in January. 
A Senate hearing that the administration hoped would be a routine check-in on the president’s 2026 MAHA-driven healthcare agenda erupted into a political firestorm as senators jumped at their first opportunity to confront HHS Secretary Robert F. Kennedy Jr. over the chaos engulfing the Centers for Disease Control and Prevention.
In December 1971, President Richard Nixon signed the National Cancer Act and declared a “War on Cancer.” In the past 54 years, the U.S. has invested $180 billion nominally, or approximately $322 billion when adjusted for inflation, in cancer research. This investment has paid dividends with more than 100 anticancer drugs brought to market in half a century—virtually all traceable to National Cancer Institute funding. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login